Table 4.
Trials of RTX use in RA/AS/SS/SLE-ILD.
| References | No of patients | Disease | RTX scheme | Follow up | Outcomes | Safety of RTX |
|---|---|---|---|---|---|---|
| Fui et al. (33) | 14 RTX vs. 14 non-RTX | RA | RA scheme | 12 m | Stable PFTs and HRCT score vs. reduced PFTs in control | No serious AE |
| Md Yusof et al. (34) | 56 | RA | RA scheme | 12 m | Increased PFTs/HRCT score | 33/56 serious AEs/infections 12/56 deaths |
| Narvaez et al. (35) | 31 | RA | RA scheme | 12 m | Improved PFTs improved/stable HRCT | Few serious AE 10/31 2/31 deaths |
| Mattesson et al. (36) | 10 | RA | RA scheme | 12 m | Stable PFTs/stable HRCT | 3/7 AEs 2/7 death |
| Vadillo et al. (37) | 31 RTX/37 non-RTX | RA | RA scheme | 6 m | Stable PFTs vs. non-stable PFTs in control group | A few AEs |
| Marie et al. (38) | 7 | AS | RA scheme | 12 m | Improved PFTs/HRCT score/steroid reduction | No serious AE |
| Doyle et al. (39) | 21 | AS | RA scheme | 12 m | Improved PFTs and HRCT/steroid reduction | No serious AE |
| Andersson et al. (40) | 24 | AS | RA scheme | 52 m | Improved PFTs and HRCT | 6/34 serious infection, 7/34 death |
| Langlois et al. (41) | 28 RTX vs. 32 CYC | AS | RA scheme | 2 y | Improved PFTs and HRCT score in both groups | Similar AE |
| Allenbach et al. (43) | 10 | AS | RA scheme | 1 y | Improve PFTs/stable HRCTscore | No serious AE |
| Chen et al. (45) | 10 | SS | RA scheme | 6 m | Improved FVC, stable DLCO,Stable HRCTscore | No serious AE |
| Reynolds et al. (49) | 11 | SLE | RA scheme (n = 9) Lymphoma scheme (n = 2) |
6 m | Stable PFTs | No serious AE |